Practice guidelines for colorectal cancer

Cancer Journal from Scientific American

Volumn 2, Issue 9999, 1996, Pages

  Venook, Alan ^a   Goodnight, James ^b   Kumar, Seema ^c   Taylor, Cat ^d   Gilden, Ron ^e   Figlin, Robert A ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c IQ Solutions   (United States)

^d Preferred Oncol Networks of America   (United States)

^e CDP Services   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; COST BENEFIT ANALYSIS; FEMALE; HUMAN; MALE; PATHOLOGY; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW;

CLINICAL TRIALS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; NEOPLASM STAGING; QUALITY OF LIFE;

EID: 0003344195     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. American Cancer Society. Cancer Facts and Figures - 1995. Atlanta: American Cancer Society, 1995.
2. Blade R, Wong WD. Recent Advances in Surgery for Colon Rectal Cancer. Curr Probl Cancer 1993;17:1.
3. National Cancer Institute. Cancer of the Colon and Rectum: Research Report. Office of Cancer Communications, NCI. NIH Publication No. 92-95, 1991.
4. Potter JD. Colon cancer: Do the nutritional epidemiology, the gut physiology and the molecular biology tell the same story? J Nutr 1993;123[2 suppl]:418-423.
5. Van Munster IP, Nagengast FM. The role of carbohydrate fermentation in colon cancer prevention. Scand J Gastroenterol 1993;200[suppl]:80-86.
6. Wargovich MJ, Lynch PM, Levin B. Modulating effects of calcium in animal models of colon carcinogenesis and short-term studies in subjects at increased risk for colon cancer. Am J Clin Nutr 1991;54[1 suppl]:202S-205S.
7. Weisburger JH, Reddy BS, Rose DP, Cohen LA, Kendall ME, Wynder EL. Protective mechanisms of dietary fibers in nutritional carcinogenesis. Basic Life Sci 1993;61:45-63.
8. Broitman SA, Cerda S, Wilkinson J. Cholesterol metabolism and colon cancer. Prog Food Nutr Sci 1993;17(1):1-40.
9. Folate, alcohol, methionine, and colon cancer risk: is there a unifying theme? Nutr Rev 1994;52(1):18-20.
10. Welberg JW, Kleibeuker JH, Van der Meer R, Mulder NH, De Bries EG. Calcium and the prevention of colon cancer. Scand J Gastroenterol 1991;188[suppl]:52-59.
11. Zimmerman J. Does dietary calcium supplementation reduce the risk of colon cancer? Nutr Rev 1993;51(4):109-112.
12. Macfarlane GJ, Lowenfels AB. Physical activity and colon cancer. Eur J Cancer Prev 1994;3(5):393-8.
13. Lynch HT. The surgeon and colorectal cancer genetics. Arch Surg 1990;125:698-702.
14. Levin B. Inflammatory bowel disease and colon cancer. Cancer 1992;70[5 suppl]:1313-6.
15. Beart RW Jr, Melton LJ, Maruta M et al. Trends in right and left sided colon cancer. Dis Colon Rectum 1983;26:393-398.
16. Selby JV, Friedman GD. Sigmoidoscopy in the periodic health examination of asymptomatic aducts. JAMA 1989;261:595-601.
17. Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with nonfamilial polyps. Ann of Intern Med 1993; 119(8):836-843.
18. Woolfson K. Tumor markers in cancer of the colon and rectum. Dis Colon Rectum 1991;34(6):506-511.
19. Dixon AK, Fry IK, Morson BC et al. Pre-operative computed tomography of carcinoma of the rectum. Br J Radiol 1981;149: 241-246.
20. Grabbe E, Lierse W, Winkler R. The perirectal fascia: morphology and use in staging of rectal carcinoma. Radiology 1983;149:241-246.
21. Freeny PC, Marks WM, Ryan JA, et al. Colorectal carcinoma evaluation with CT: preoperative staging and detection of postoperative recurrence. Radiology 1986;158:347-353.
22. Thompson WM, Halvorsen RA, Foster WL, Jr. et al. Preoperative and postoperative CT staging of rectosigmoid carcinoma Am J Roentgenol 1986;146:703-710.
23. Zaunbaner W, Haertel M, Fuchs WA. Computed tomography in carcinoma of the rectum. Gastrointest Radiol 1981;6:79-84.
24. Adakstenbssib B, Glimelius B, Graffman S, et al. Computed tomography in staging of rectal carcinoma. ACTA Radiologica Diagnosis 1985;26:45-55.
25. Kodner IJ, Gilley MT, Shemesh EI et al. Radiation therapy as definitive treatment for selected invasive rectal cancer. Surgery 1993;114(4):850-857.
26. Boyce GA, Sivak MV Jr, Lavery IC et al. Endoscopic ultrasound in the pre-operative staging of rectal carcinoma. Gastrointest Endosc 1992;38(4):468-471.
27. Lindmark G, Elvin A, Pahlman L, Glimelius B. The value of endosonography in preoperative staging of rectal cancer. Int J Colorectal Dis 1992;7(3):162-166.
28. Tio TL, Weijers O, Hulsman F et al. Endosonography of colorectal diseases. Endoscopy. 1992;24[suppl 1]:309-314.
29. Tio TL, Coene PP, van Delden OM, Tytgat GN. Colorectal carcinoma: preoperative TNM classification with endosonography. Radiology 1991;179(1):165-170.
30. Chang KJ, Katz KD, Durbin TE et al. Endoscopic ultrasound guided fine needle aspiration. Gastrointest Endosc 1994;40(6): 694-699.
31. Beynon J, Foy DMA, Roe AM et al. Endoluminal ultrasound in the assessment of local invasion in rectal cancer. Br J Surg 1986; 73:474-477.
32. Wolmark N, Fisher B, Rockette H et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Nad Cancer Inst 1988;80(1):1-29.
33. Laurie JA, Moertel CG, Fleming TR et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7(10):1447-1456.
34. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New Engl J Med 1990;332(6):352-358.
35. PDQ. Colon Cancer State-of-the-Art Treatment, October 24, 1994, National Cancer Institute, Bethesda, Maryland.
36. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel project protocol C-03. J Clin Oncol 1993; 11(10):1879-1887.
37. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994;330(16):1136-1142.
38. Willen CG, Tepper JE, Skates SJ et al. Adjuvant postoperative radiation therapy for colonic carcinoma. Ann Surg 1987;206(6): 694-698.
39. National Institutes of Health. NIH Consensus Development Conference: adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264(11):1444-1450.
40. Fisher B. National Surgical Adjuvant Breast and Bowel Project-phase III randomized comparison of 5-FU/CF vs. 5-FU/LEV vs. 5-FU/CF/LEV as adjuvant therapy following potentially curative resection of Dukes' B and C carcinoma of the colon, NSABP-C-04, clinical trial, closed, 12/31/90.
41. Scheele J, Stangl R, Altendorf-Hofmann A et al. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990;77(11):1241-1246.
42. Scheele J, Stangl R, Altendorf-Hofmann A et al. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991;110(1):13-29.
43. Wagman LD, Kemeny MM, Leong L et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990;8(11):1885-1893.
44. Adson MA, van Heerdan JA, Wagner JS et al. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984;119(6):647-651.
45. Coppa GF, Eng K, Ranson JH et al. Hepatic resection for metastatic colon and rectal cancer. Ann Surg 1985;202(2):203-208.
46. Valone FH, Friedman MA, Wittlinger PS et al. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high dose leucovorin plus fluorouracil or sequential methotrexate, fluorouracil, leucovorin : a randomized trial of the Northern California Oncology Group. J Clin Oncol 1989;7(10): 1427-1436.
47. Petrelli N, Douglass HO, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989;7(10):1419-1426.
48. Erlichman C, Fine S, Wong A et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988;6(3):469-475.
49. Doroshow JH, Multhauf O, Leong L et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990;8(3):491-501.
50. Wadler S, Lembersky B, Atkins M et al. Phase II trial of fluorouracil and recombinant Interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1991;9(10):1806-1810.
51. Poon MA, O'Connell MJ, Wieand HS et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9(11):1967-1972.
52. Grem JL, Jordan E, Robson ME et al. Phase II study of fluorouracil, leucovorin, and Interferon alpha-2a in metastatic colorectal carcinoma. J Clin Oncol 1993;11(9):1737-1745.
53. Gunderson LL, Sosin H. Areas of failure found at reoperation (second or symptomatic look) following "curative surgery" for adenocarcinoma of the rectum: clinicopathologic correlation and implications for adjuvant therapy. Cancer 1974;34(4):1278-1292.
54. Twomey P, Burchell M, Strawn D et al. Local control in rectal cancer: a clinical review and meta-analysis. Arch Surg 1989; 124(10):1174-1179.
55. Mohiuddin M, Marks G. Adjuvant radiation therapy for colon and recral cancer. Semin Oncol 1991;18(5):411-420.
56. Gerard A, Buyse M, Nordlinger B et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer: final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988;208(5):606-614.
57. Marks G, Mohiuddin M, Masoni L. The reality of radical sphincter preservation surgery for cancer of the distal 3 cm of rectum following high-dose radiation. Int J Radiat Oncol Biol Phys 1993;27(4):779-783.
58. Weaver D, Lindblad AS. Radiation therapy and 5-fluorouracil (5-fu) with or without MeCCNU for the treatment of patients with surgically adjuvant adenocarcinoma of the rectum. Proc Annu Meet Am Soc Clin Oncol 1990;9:A409.
59. Gastrointestinal Tumor Study Group: Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 1992;10(4):549-557.
60. Bailey HR, Huval WV, Max E et al. Local excision of carcinoma of the rectum for cure. Surgery 1992;111(5):555-561.
61. Eisenstat TE, Oliver GC. Electrocoagulation for adenocarcinoma of the low rectum. World J Surg 1992;16(3):458-462.
62. Thomas PR, Lindblad AS. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. Radiother Oncol 1988;13(4):245-252.
63. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. New Engl J Med 1991;324(11):709-715.
64. Wolmark N, Fisher B. An analysis of survival and treatment failure following abdominoperineal and sphincter-saving resection in Dukes' B and C rectal carcinoma: a report of the NSABP clinical trials. Ann Surg 1986;204(4):480-489.
65. Tepper JE. Cancer and Leukemia Group B: NCI HIGH PRIORITY CLINICAL TRIAL - phase III randomized comparison of four systemic regimens combined with pelvic irradiation as adjuvant therapy for totally resected stage II/III adenocarcinoma of the rectum: 5-FU vs 5-FU/LEV vs 5-FU/CF/LEV (Summary Last Modified 8/92), CLB-9081, clinical trial, closed, 11/22/1992.
66. Fisher B. National Surgical Adjuvant Breast and Bowel Project: NCI high priority clinical trial-phase III randomized comparison of adjuvant chemotherapy with MOF (MeCCNU/VCR/5-FU) with and without radiotherapy vs. 5-FU plus high-dose CF with and without radiotherapy following curative resection of Dukes' B and C adenocarcinoma of the rectum, NSABP-R-02, clinical trial, completed, 12/30/92.
67. Rougier P, Nordlinger B. Large scale trial for adjuvant treatment in high risk resected colorectal cancers: rational to test the combination of loco-regional and systemic chemotherapy and to compare 1-leucovorin and 5-FU to levamisole and 5-FU. Ann Oncol 1993;4[suppl 2]:S21-S28.
68. PDQ. Rectal Cancer State-of-the-Art Treatment, November 1, 1994, National Cancer Institute, Bethesda, Maryland.
69. Fisher B, Wolmark N, Rockette H et al. Postopetative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Nad Cancer Inst 1988;80(1):21-29.
70. O'Connell M, Wieand H, Krook J et al. Lack of value for methyl-CCNU (MeCCNU) as a component of effective rectal cancer surgical adjuvant therapy: interim analysis of intergroup protocol 86-47-51. Proc Am Soc Clin Oncol 1991;10:A-403,134.
71. Buroker TR, O'Connell MJ, Wieand HS et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12(1):14-20.
72. Lokich JJ. Colon and Rectal Cancer. In: Lokich JJ., ed. Cancer Chemotherapy by Infusion. 2nd ed. Chicago: Precept Press, 323-339.
73. Patterson WB. Oncology perspective on colorectal cancet in the geriatric patient. Aging 1983;24:105-112.
74. Fitzgerald SD, Longo WE, Daniel GL, Vernava AM. Advanced colorectal neoplasia in the high-risk elderly patient: is surgical resection justified? Dis Colon Rectum 1993;36(2):161-166.
75. Kluger Y, Shilone E, Jurim O et al. Subtotal colectomy with primary ileocolonic anastomosis for obstructing carcinoma of the left colon: valid option for elderly high-risk patients. Isr J Med Sci 1993;29(11):726-730.
76. Catalano MF, Levin B. Cancer of the colon and rectum. Clin Geriatr Med 1991;7(2):331-346.
77. Baba S, Ogiwara H,. Nakamura T, Teramoto T. Extended lymphadenectomy and the quality of life in rectal cancer patients. Int Surg 1994;79(1):23-26.
78. Delfino C, Caccia G, Maniago O, Bosch B. Chemotherapy vs supportive care in patients with advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1993;12: A630.
79. Humphrey LJ. Cost-benefit impact on cancer screening. Semin Surg Oncol 1989;5:205.
80. Heine JA, Rothenberger DA. Cost-effective management of colon and rectal cancer. World J Surg 1991;15(5):597-604.
81. Rosen P, Ron EA. Cost analysis of screening methodology for family members of colorectal cancer patients. Am J Gastroenterol 1989;84:1548.
82. Lokich J, Anderson N, Bern M, Zipoli T. Comparison cost of three chemotherapy regimens for advanced colon cancer: 5-fluorouracil (5FU) + leucovorin (LVC), 5FU + interferon (IFN), and protracted-infusion 5FU (PIF) (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1991;10:A436.
83. Kievit J, van de Velde CJH. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation: a Markov analysis. Cancer, 1990;65:2580.
84. Haggitt RC, Glotzbach RE, Soffer EE et al. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterol 1985;89: 328-336.
85. Steele G Jr. Standard postoperative monitoring of patients after primary resection of colon and rectum cancer. Cancer 1993; 71[suppl]:4225-4235.